ArticleScientific reports2025
Anticancer potential of Dendrocnide meyeniana through phytochemical profiling, ADMET analysis, molecular docking, and in silico cytotoxicity evaluation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Phytochemicals are widely explored for cancer therapeutics due to their structural diversity and broad pharmacological activities. This study investigated the phytochemical composition and anticancer potential of Dendrocnide meyeniana using integrated in silico approaches. Gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) identified 78 compounds, confirming the plant's rich chemical diversity. Four cancer-related targets- EGFR, p53, MMP7 and CDK8/Cyclin C were selected for molecular docking to identify potential inhibitors. Drug-likeness and ADMET profiling of nine bioactive candidates revealed Cryptotanshinone as the most promising compound, exhibiting favorable pharmacokinetic and safety properties. Molecular docking showed that Cryptotanshinone possessed strong binding affinities toward EGFR ( -8.8 kcal/mol), p53 (-8.7 kcal/mol), MMP7 (-8.7 kcal/mol), and CDK8/Cyclin C (-9.8 kcal/mol), comparable to or exceeding the reference drug Erlotinib (-9.0 kcal/mol for EGFR). Toxicity prediction indicated no hepatotoxic, mutagenic, or cytotoxic effects, though the compound showed potential carcinogenic activity possibly linked to pathway-specific interaction in cell-cycle regulation. Molecular dynamics simulation further validated the stability of the Cryptotanshinone-EGFR complex, exhibiting moderate RMSD values and limited structural fluctuations indicative of stable interactions. Collectively, these findings highlight Cryptotanshinone from D. meyeniana as a promising natural lead for anticancer drug development, characterized by strong binding affinity, favorable pharmacokinetics, and structural stability in silico. Further in vitro and in vivo studies are warranted to confirm its therapeutic efficacy and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.